Omfattande molekylär karakterisering av kronisk lymfatisk leukemi

Tidsperiod: 2013-01-01 till 2016-12-31

Finansiär: Vetenskapsrådet

Bidragstyp: Projektbidrag

Budget: 3 800 000 SEK

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. The disease is clinically and biologically heterogeneous and remains incurable. The etiology is unknown. Our main goals of this translational research program are to increase our understanding of the mechanisms behind disease development, to improve and optimize diagnostic/prognostic information as well as to study clonal evolution. In the present study we will perform a comprehensive investigation of the molecular characteristics in a large CLL cohort and integrate our findings with clinical data. More specifically, our aims are as follows: 1. To investigate genetic and epigenetic events involved in CLL patogenesis and to improve the subgrouping of CLL into subsets with different prognoses and management, by applying state-of-the-art technology, including next-generation sequencing. 2. To evaluate a group of new biological prognostic markers together with clinical information, and to develop a CLL international prognostic index. 3. To study clonal evolution in terms of genetic/epigenetic aberrations in CLL samples procured over time from patients responding to treatment and non-responders. In parallel, perform drug sensitivity screening at diagnosis and relapse. This project will significantly improve our knowledge about key mechanisms involved during leukemogenesis and optimize the diagnostic and prognostic information in CLL which ultimately will lead to improved treatment strategies.